Journal article
Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
Abstract
Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an important tool to help guide treatment decisions. The clinical value of MRD testing depends on the accuracy and reliability of results. Currently, there are no Canadian provincial or national guidelines for MRD testing in adult B-ALL, and consistent with the absence of …
Authors
Tierens A; Stockley TL; Campbell C; Fulcher J; Leber B; McCready E; Sabatini PJB; Sadikovic B; Schuh AC
Journal
Current Oncology, Vol. 28, No. 2, pp. 1376–1387
Publisher
MDPI
DOI
10.3390/curroncol28020131
ISSN
1198-0052